SCHEMBL3307176

SCHEMBL3307176

COc1ccc(C(=O)C=Cc2ccc(O)c(CC=C(C)C)c2)c(O)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.79
CYP19A1 P11511 1/20 0.72
ABCG2 Q9UNQ0 6/20 0.66
LMNA P02545 3/20 0.66
MAPT P10636 3/20 0.66
MEN1 O00255 2/20 0.66
CYP3A4 P08684 2/20 0.66
MAPK1 P28482 2/20 0.66
KMT2A Q03164 2/20 0.66
APP P05067 2/20 0.66
CYP2C19 P33261 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
MAOB P27338 3/20 0.64
MGAM O43451 1/20 0.64
MAOA P21397 1/20 0.64
XDH P47989 1/20 0.64
FLT3 P36888 1/20 0.63
AKR1B10 O60218 1/20 0.61
AKR1B1 P15121 1/20 0.61
AKR1C3 P42330 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3307174 1.00 PTPN1 (0.79) PTPN1CYP19A1ABCG2LMNAMAPT
SCHEMBL30383478 1.00 PTPN1 (0.79) PTPN1CYP19A1ABCG2LMNAMAPT
SCHEMBL30383825 0.91 CYP19A1 (0.86) PTPN1CYP19A1ABCG2LMNAMAPT
SCHEMBL3304113 0.91 CYP19A1 (0.86) PTPN1CYP19A1ABCG2LMNAMAPT
SCHEMBL3304114 0.91 CYP19A1 (0.86) PTPN1CYP19A1ABCG2LMNAMAPT
Licoagrochalcone A SCHEMBL632908 0.89 PTPN1 (1.00) PTPN1CYP19A1ABCG2LMNAMAPT
Licoagrochalcone A SCHEMBL632907 0.89 PTPN1 (1.00) PTPN1CYP19A1ABCG2LMNAMAPT
Licoagrochalcone A SCHEMBL30384736 0.89 PTPN1 (1.00) PTPN1CYP19A1ABCG2LMNAMAPT
SCHEMBL30384161 0.87 CYP19A1 (0.72) PTPN1CYP19A1ABCG2LMNAMAPT
SCHEMBL3305925 0.87 CYP19A1 (0.72) PTPN1CYP19A1ABCG2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-8946287-B2 Chemotherapeutic flavonoids, and syntheses thereof PURDUE RESEARCH FOUNDATION (US) 2015-02-03 US disclosed
US-20100099755-A1 CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF PURDUE RESEARCH FOUNDATION (US) 2010-04-22 US disclosed
WO-2008076767-A1 CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF PURDUE RESEARCH FOUNDATION (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099755-A1 CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF NRAS, FAU, DPYD PTPN1 4272/4885CYP19A1 104/4885ABCG2 7/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B PTPN1 1308/4885CYP19A1 270/4885ABCG2 1606/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 PTPN1 1520/4885CYP19A1 320/4885ABCG2 3622/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 PTPN1 1520/4885CYP19A1 320/4885ABCG2 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.